Related Experiment Videos
Leu-M1 antigen expression in acute leukaemias
A de Mascarel1, J M Coindre, I de Mascarel
1Laboratoire d'Anatomie-Pathologique, Université de Bordeaux II, France.
The Journal of Pathology
|November 1, 1987
Summary
The Leu-M1 antigen is present in acute myeloid leukemia (AML) and some acute lymphoblastic leukemia (ALL) cases. This study found Leu-M1 is not useful for distinguishing AML from ALL or for classifying ALL subtypes.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Leu-M1 is a differentiation antigen found on human myelomonocytic cells.
- Accurate classification of leukemias and lymphomas is crucial for effective treatment.
Purpose of the Study:
- To evaluate the utility of the Leu-M1 antibody in differentiating acute myeloid leukemia (AML) from acute lymphoblastic leukemia (ALL).
- To assess the role of Leu-M1 in classifying subtypes of ALL and high-grade malignant lymphomas.
Main Methods:
- Retrospective analysis of 77 acute leukemia cases (44 ALL, 33 AML) using immunoperoxidase staining on paraffin-embedded sections with anti-Leu-M1 antibody.
- Comparison of Leu-M1 staining results with established cytochemical and cell suspension immunologic markers.
- Evaluation of Leu-M1 reactivity on paraffin sections of 34 high-grade malignant lymphomas.
Main Results:
- Leu-M1 was positive in all AML cases and approximately half of ALL cases, indicating it cannot differentiate between these two major leukemia types.
- In ALL cases, Leu-M1 positivity was observed across B-cell, T-cell, and 'null'-cell subtypes without clear discriminatory patterns.
- Leu-M1 was negative in B-cell and 'null'-cell lymphomas but positive in some peripheral T-cell lymphomas, suggesting differential expression in lymphoma subtypes.
Conclusions:
- The Leu-M1 antibody is not a reliable marker for distinguishing AML from ALL.
- Leu-M1 expression does not aid in the subclassification of ALL.
- Leu-M1 may have some utility in identifying T-cell lymphomas but is negative in B-cell lymphomas.